Pricing Log in Create free account

ProQR Therapeutics N.V. (PRQR) vs Cartesian Therapeutics, Inc. (RNAC)

ProQR Therapeutics N.V. and Cartesian Therapeutics, Inc. are both Biotechnology companies. ProQR Therapeutics N.V. and Cartesian Therapeutics, Inc. are of similar size ($204.6M and $199.1M). ProQR Therapeutics N.V. grew revenue faster over the last twelve months: 19.7% against −94.8%. Cartesian Therapeutics, Inc. has the higher net margin (0.00% vs −228.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Cartesian Therapeutics, Inc. leads on 8 and ProQR Therapeutics N.V. on 6.

Valuation

Metric PRQR RNAC Biotechnology median
P/E n/m n/m 8.50
P/S 6.71 104.09 9.71
P/B 1.56 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.85 56.47 9.21
Earnings yield (35.11%) (94.58%) (33.15%)
Free cash flow yield (39.84%) (42.55%) (25.50%)

Profitability

Metric PRQR RNAC Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (233.33%) 0.00% 0.00%
Net margin (228.71%) 0.00% 0.00%
Free cash flow margin (267.36%) 0.00% 0.00%
Return on equity (58.29%) 236.88% (56.36%)
Return on assets (31.53%) (42.77%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PRQR RNAC Biotechnology median
Revenue growth (TTM) 19.72% (94.81%) 6.02%
EPS growth (last fiscal year) (28.57%) (11.80%) 30.26%
Revenue growth, 5-year CAGR — (29.96%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PRQR RNAC Biotechnology median
Debt to equity 0.06 (0.42) 0.00
Current ratio 3.49 7.48 4.72
Net debt to EBITDA 2.15 0.89 0.96

Dividend

Metric PRQR RNAC Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric PRQR RNAC Biotechnology median
Market cap 204.63m 199.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack